Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $47.14 Average PT from Brokerages

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) have received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $47.5714.

CSTL has been the topic of a number of recent research reports. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, February 2nd. BTIG Research upped their price objective on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Canaccord Genuity Group increased their price objective on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Finally, KeyCorp restated an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a research note on Thursday, January 29th.

Castle Biosciences Stock Down 7.2%

Shares of Castle Biosciences stock opened at $29.57 on Thursday. The company has a market capitalization of $863.15 million, a P/E ratio of -34.79 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The business has a 50-day moving average of $37.17 and a two-hundred day moving average of $31.21. Castle Biosciences has a 1 year low of $14.59 and a 1 year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The firm had revenue of $81.88 million for the quarter, compared to analysts’ expectations of $81.19 million. As a group, equities analysts predict that Castle Biosciences will post 0.44 EPS for the current year.

Insiders Place Their Bets

In related news, COO Kristen M. Oelschlager sold 14,888 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total transaction of $585,247.28. Following the sale, the chief operating officer owned 12,323 shares in the company, valued at $484,417.13. The trade was a 54.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 817 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total value of $31,037.83. Following the completion of the transaction, the insider directly owned 83,698 shares of the company’s stock, valued at $3,179,687.02. This represents a 0.97% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 29,617 shares of company stock worth $1,167,887. Company insiders own 6.50% of the company’s stock.

Institutional Trading of Castle Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Amundi boosted its holdings in Castle Biosciences by 15,811.5% during the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after purchasing an additional 4,111 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Castle Biosciences by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after buying an additional 655 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Castle Biosciences by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after acquiring an additional 707 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Key Headlines Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 revenue guide: Castle reported FY2025 revenue of $344M (above guidance) with Q4 revenues roughly in line with estimates and beat on EPS (Q4 GAAP EPS -$0.08 vs. consensus -$0.23). Management set 2026 revenue guidance of $340–$350M (slightly above the prior consensus ~$335M), supporting near‑term top‑line growth expectations. Castle Biosciences outlines 2026 revenue target
• Positive Sentiment: Product momentum and new launch: Core test reports (DecisionDx‑Melanoma and TissueCypher) rose ~37% in 2025 (TissueCypher +86%), and Castle launched AdvanceAD‑Tx (limited access), which expands the addressable market in atopic dermatitis. These operational wins support longer‑term growth potential. Earnings press release
• Positive Sentiment: Analyst upgrade / price target lift: Robert W. Baird raised its price target to $44 and reiterated an Outperform rating, signaling bullish analyst sentiment and implying notable upside from current levels. Baird raises target
• Neutral Sentiment: Additional coverage & materials: Earnings and investor materials (call transcript, slide deck) are available for deeper due diligence — useful for active investors reviewing guidance detail and management commentary. Press release & slide deck
• Neutral Sentiment: Street view: Recent coverage shows a generally constructive analyst stance (average “Moderate Buy” / multiple buy/outperform ratings), which can support sentiment if fundamentals hold. Analyst ratings roundup
• Negative Sentiment: Profitability and accounting headwinds: Despite revenue growth, Castle reported a GAAP net loss for 2025 of $24.2M (vs. net income in 2024) and adjusted EBITDA declined materially (from $75M to $44M). A one‑time acceleration of amortization (IDgenetix) and other items reduced margins — a drag on near‑term earnings power. Zacks earnings summary
• Negative Sentiment: Insider selling and discontinued tests: Public filings and summaries show heavy insider sales in recent months and the discontinuation of IDgenetix (lost volume), both of which can pressure sentiment and raise governance/operational questions for investors. Quiver / results summary

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.